Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06054698
PHASE2

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

To assess the efficacy of HRS9531 injection compared with placebo in weight reduction in overweight or obese subjects after 36 weeks of treatment.

Official title: A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Overweight or Obese Subjects

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

61

Start Date

2023-10-16

Completion Date

2024-09-09

Last Updated

2026-05-22

Healthy Volunteers

No

Interventions

DRUG

HRS9531 injection

HRS9531 injection , QW,36 weeks

DRUG

HRS9531 injection Placebo

HRS9531 injection Placebo,QW,36 weeks

Locations (4)

The Affiliated Hospital of Xuzhou Medicine University

Xuzhou, Jiangsu, China

Jinan Central Hospital

Jinan, Shandong, China

Zhejiang Hospital

Hangzhou, Zhejiang, China

Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine

Hangzhou, Zhejiang, China